^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    PIM3 (Pim-3 Proto-Oncogene)

    i
    Other names: PIM3, Pim-3 Proto-Oncogene, Serine/Threonine Kinase, Serine/Threonine-Protein Kinase Pim-3, Pim-3 Oncogene, Serine/Threonine Kinase Pim-3, Pim-3
    Associations

    News

    Trials
    over1year
    Low miR-936-mediated upregulation of Pim-3 drives sorafenib resistance in liver cancer through ferroptosis inhibition by activating the ANKRD18A/Src/NRF2 pathway. (PubMed, Front Oncol)
    Moreover, the elevated expression of Pim-3, resulting from the absence of miR-936 enhances sorafenib resistance in liver cancer by inhibiting cell ferroptosis. Pim-3 can be regarded as a target in the treatment of sorafenib-resistant liver cancer.
    Journal
    |
    HMOX1 (Heme Oxygenase 1) • GPX4 (Glutathione Peroxidase 4) • NQO1 (NAD(P)H dehydrogenase, quinone 1) • TFRC • SLC7A11 (Solute Carrier Family 7 Member 11) • DMRT1 (Doublesex And Mab-3 Related Transcription Factor 1) • MIR936 (MicroRNA 936) • PIM3 (Pim-3 Proto-Oncogene)
    |
    HMOX1 expression • SLC7A11 expression
    |
    sorafenib
    almost2years
    PIM Kinase Inhibition Sensitizes Neuroblastoma to Doxorubicin. (PubMed, J Pediatr Surg)
    The correlation between PIM and ABCC1 gene expression suggests PIM kinases may contribute to neuroblastoma chemotherapeutic resistance. PIM kinase inhibition increased intracellular doxorubicin accumulation. Combination treatment with AZD1208 and doxorubicin decreased neuroblastoma cell viability in a synergistic fashion. These findings support further investigations of PIM kinase inhibition in neuroblastoma.
    Journal
    |
    ABCC1 (ATP Binding Cassette Subfamily C Member 1) • PIM1 (Pim-1 Proto-Oncogene) • PIM3 (Pim-3 Proto-Oncogene)
    |
    doxorubicin hydrochloride • AZD1208
    2years
    PIM3 Kinase: A Promising Novel Target in Solid Cancers. (PubMed, Cancers (Basel))
    This review provides an overview of recent developments and insights into the role of PIM3 in various cancers and its potential as a novel molecular target for cancer therapy. We also discuss the current status of PIM-targeted therapies in clinical trials.
    Review • Journal
    |
    PIM1 (Pim-1 Proto-Oncogene) • PIM3 (Pim-3 Proto-Oncogene)
    2years
    Identification and assessment of new PIM2 inhibitors for treating hematologic cancers: A combined approach of energy-based virtual screening and machine learning evaluation. (PubMed, Arch Pharm (Weinheim))
    Molecular dynamics simulations elucidated the binding mode of compound 2 with PIM2, offering insights for drug development. These results highlight the reliability and efficacy of our virtual screening workflow, promising new drugs for hematologic cancers, notably ALCL.
    Journal • Machine learning
    |
    PIM1 (Pim-1 Proto-Oncogene) • PIM3 (Pim-3 Proto-Oncogene)
    2years
    Corynoline inhibits esophageal squamous cell carcinoma growth via targeting Pim-3. (PubMed, Phytomedicine)
    Our findings suggest that Pim-3 promotes ESCC progression. Corynoline inhibits ESCC progression through targeting Pim-3.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • MAPK1 (Mitogen-activated protein kinase 1) • CASP9 (Caspase 9) • PIM3 (Pim-3 Proto-Oncogene)
    over2years
    LncRNA SNHG1 Accelerates Cell Proliferation, Migration, and Invasion of Hepatoblastoma Through Mediating miR-6838-5p/PIM3/RhoA Axis. (PubMed, Biochem Genet)
    What's more, the results at the cellular level were further verified by nude mice tumor formation experiment. In conclusion, SNHG1 regulated miR-6838-5p/PIM3/RhoA axis to promote malignant phenotypes of HB, which might provide novel therapeutic target for HB treatment.
    Journal
    |
    RHOA (Ras homolog family member A) • SNHG1 (Small Nucleolar RNA Host Gene 1) • PIM3 (Pim-3 Proto-Oncogene)
    almost3years
    Inhibition of PIM Kinases Promotes Neuroblastoma Cell Differentiation to a Neuronal Phenotype. (PubMed, J Pediatr Surg)
    Inhibition of PIM kinases differentiated neuroblastoma cancer cells toward a neuronal phenotype. Differentiation is a key component of preventing neuroblastoma relapse or recurrence and PIM kinase inhibition provides a potential new therapeutic strategy for this disease.
    Journal
    |
    SOX2 • PIM1 (Pim-1 Proto-Oncogene) • POU5F1 (POU Class 5 Homeobox 1) • NANOG (Nanog Homeobox) • PIM2 (Pim-2 Proto-Oncogene, Serine/Threonine Kinase) • PIM3 (Pim-3 Proto-Oncogene)
    |
    AZD1208
    almost3years
    NATURAL FLAVONOIDS INHIBIT MYELOID NEOPLASM PROLIFERATION BY REGULATING PIM2 KINASE ACTIVITY (EHA 2023)
    Kaempferol and Quercetin Dihydrate inhibit proliferation and induce apoptosis of myeloid neoplasms cells. PIM2 is an important target for the development and prognosis of acute myeloid leukemia and MDS. Kaempferol and Quercetin Dihydrate inhibit PIM2 kinase in myeloid neoplasms cells and subsequently participate in NF-κB expression, proliferation and regulation of myeloid neoplasms.
    IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • PIM1 (Pim-1 Proto-Oncogene) • GLI2 (GLI Family Zinc Finger 2) • PIM3 (Pim-3 Proto-Oncogene)
    |
    BCL2 expression • BAX expression • NFKB1 expression
    |
    AZD1208 • Q-Force (quercetin)
    almost3years
    Characterizing the role of PIM kinases in the prostate tumor immune microenvironment. (ASCO 2023)
    Our data suggest a strong association between PIM expression and increased MAPK activation score, T cell inflamed score, inflammatory, MHC class I and MHC class II gene expression, and differential immune cell infiltration. A better understanding of these differences will provide a rationale for tailored therapeutic approaches for PIM-expressing PC.
    KRAS (KRAS proto-oncogene GTPase) • AR (Androgen receptor) • IL6 (Interleukin 6) • B2M (Beta-2-microglobulin) • STAT3 (Signal Transducer And Activator Of Transcription 3) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • IL2 (Interleukin 2) • PIM1 (Pim-1 Proto-Oncogene) • HLA-B (Major Histocompatibility Complex, Class I, B) • TGFB1 (Transforming Growth Factor Beta 1) • HLA-DPA1 (Major Histocompatibility Complex, Class II, DP Alpha 1) • IL1B (Interleukin 1, beta) • TAP1 (Transporter 1) • HLA-C (Major Histocompatibility Complex, Class I, C) • KLK3 (Kallikrein-related peptidase 3) • PIM3 (Pim-3 Proto-Oncogene) • TNFSF13 (TNF Superfamily Member 13)
    |
    AR expression • MHC-II expression • PIM1 overexpression
    |
    MI Tumor Seek™